Laura Shawver - Feb 1, 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)

Role
Chief Executive Officer, Director
Signature
/s/ Jeffrey C. Pepe, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 04:17 PM
Previous filing
Jun 15, 2021
Next filing
May 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Award $0 +27.5K +34.42% $0.00 107K Feb 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (right to buy) Award $0 +165K $0.00 165K Feb 1, 2022 Common Stock 165K $4.85 Direct F3
transaction SPRY Stock Option (right to buy) Award $0 +105K $0.00 105K Feb 1, 2022 Common Stock 105K $4.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 682 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021.
F3 The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
F4 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.